The goal of this study was to evaluate shorter duration (3 months) dual antiplatelet therapy (DAPT) after drug-eluting stent (DES) implantation. There have been few published reports of prospective randomized clinical studies comparing the safety and efficacy of shorter duration DAPT after DES implantation. We randomly assigned 2,117 patients with coronary artery stenosis into 2 groups according to DAPT duration and stent type:3-month DAPT following Endeavor zotarolimus-eluting stent (E-ZES) implantation (E-ZES+3-month DAPT,n = 1,059) versus 12-month DAPT following the other DES implantation (standard therapy,n = 1,058). We hypothesized that the E-ZES+3-month DAPT would be noninferior to the standard therapy for the primary composite endpoint (cardiovascular death,myocardial infarction,stent thrombosis,target\vessel revascularization,or bleeding) at 1 year. The primary endpoint occurred in 40 (4.7%) patients assigned to E-ZES+3-month DAPT compared with 41 (4.7%) patients assigned to the standard therapy (difference:0.0%;95% confidence interval [CI]:−2.5 to 2.5;p = 0.84;p < 0.001 for noninferiority). The composite rates of any death,myocardial infarction,or stent thrombosis were 0.8% and 1.3%,respectively (difference:−0.5%;95% CI:−1.5 to 0.5;p = 0.48). The rates of stent thrombosis were 0.2% and 0.3%,respectively (difference:−0.1%;95% CI:−0.5 to 0.3;p = 0.65) without its further occurrence after cessation of clopidogrel in the E-ZES+3-month DAPT group. The rates of target vessel revascularization were 3.9% and 3.7%,respectively (difference:0.2%;95% CI:−2.3 to 2.6;p = 0.70). E-ZES+3-month DAPT was noninferior to the standard therapy with respect to the occurrence of the primary endpoint. (REal Safety and Efficacy of a 3-month dual antiplatelet Therapy following E-ZES implantation [RESET];NCT01145079)
Journal of the American College of Cardiology Current Issue
Objectives
Background
Methods
Results
Conclusions
